Sleep disorders are highly prevalent non-motor symptoms (NMS) in Parkinson’s disease (PD). These can significantly contribute to deterioration in quality of life (QoL), especially during the advanced phase of the disease. Dopaminergic replacement therapy is the mainstay of PD treatment and may alleviate some NMS. Device-aided therapies can be considered when motor fluctuations and dyskinesia are not optimally managed by oral dopaminergic therapy.
Sleep quality improvement after switching from levodopa/carbidopa intestinal gel to continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: a case report / De Carolis, Lanfranco; Pacilio, Pierre; Bianchini, Edoardo; Salvetti, Marco; Rinaldi, Domiziana. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 47:3(2026). [10.1007/s10072-026-08854-3]
Sleep quality improvement after switching from levodopa/carbidopa intestinal gel to continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: a case report
De Carolis, Lanfranco;Pacilio, Pierre;Bianchini, Edoardo;Salvetti, Marco;Rinaldi, Domiziana
2026
Abstract
Sleep disorders are highly prevalent non-motor symptoms (NMS) in Parkinson’s disease (PD). These can significantly contribute to deterioration in quality of life (QoL), especially during the advanced phase of the disease. Dopaminergic replacement therapy is the mainstay of PD treatment and may alleviate some NMS. Device-aided therapies can be considered when motor fluctuations and dyskinesia are not optimally managed by oral dopaminergic therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
